Navigation Links
Common epilepsy drug could prevent and treat Alzheimer's disease
Date:10/27/2008

The team led by UBC Psychiatry Prof. Weihong Song, who is also the Jack Brown and Family Professor and Chair in Alzheimer's Disease at UBC, found that if Valproic Acid (VPA) is used as a treatment in early stages of AD memory deficit is reversed.

The study, published in the Journal of Experimental Medicine, reveals that VPA works by inhibiting the activity of an enzyme that produces a neurotoxic protein called beta Amyloid. In doing so, plaque formation is discontinued. Amyloid beta-proteins are the central component of neurotoxic plaques in AD.

"We found that if we used VPA in the early stage of Alzheimer's disease, in model mice, it reduced plaque formation and further prevented brain cell death and axon damage," says Song, who is a Canada Research Chair in Alzheimer's disease and Director of the Townsend Family Laboratories in UBC's Faculty of Medicine. "The drug also improved performance in memory tests."

The results will help inform the design of human clinical trials because researchers now understand the mechanisms and pathology of VPA in AD animal models.

"We are very excited about these results because we now know when VPA should be administered to be most effective and we now know how VPA is working to prevent AD," says Song, who is also a member of the Brain Research Centre at UBC and VCHRI. "A small human clinical trial is currently underway and we expect results to be available in the next year."

AD is a neurodegenerative disorder characterized by progressive cognitive deterioration and is the most common form of dementia. The Alzheimer Society of Canada estimates that AD affects close to 300,000 Canadians and accounts for two-thirds of all cases of dementia. By 2031, about 750,000 Canadians will suffer from AD and related dementias.


'/>"/>

Contact: Catherine Loiacono
catherine.loiacono@ubc.ca
604-822-2644
University of British Columbia
Source:Eurekalert

Page: 1

Related medicine news :

1. Westaim to deregister its common stock in the United States
2. Vision loss more common in people with diabetes
3. deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer
4. LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis
5. National study finds post-traumatic stress disorder common among injured patients
6. Common painkillers lower levels of prostate cancer biomarker
7. Survey: Tanorexia common among university students
8. Depression common among Rwandan youth who head households
9. Commonwealth Medical Group Physicians to Join Aurora Health Care
10. Longs Drug Stores Corporation Declares Cash Dividend on Common Shares
11. Enhanced Care Initiatives (HC Innovations, Inc.) Contracts with HIP and GHI to Create a Medical Home Network Project with Support from the Commonwealth Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... , ... Delta Dental of California and its affiliated companies announced today that ... who recently retired as president and CEO of Delta Dental of California and its ... Year , helped lead the effort to raise funds for studies to strengthen pancreatic ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to a product from ... a cluster of melanin when exposed to sunlight. Although most moles are benign and ... embarrassment. Historically, mole removal has involved a painful, often expensive visit to ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... four states in the U.S. require dental technicians to be certified or obtain ... dental industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)...  Astellas Pharma Inc. President and Chief Executive Officer ... Robinson as president, Americas Operations, for Astellas US LLC, ... South America , effective April 1, 2016.  Robinson ... organization in the United States -- ... Yoshida , who is retiring in June 2016.  ...
(Date:2/8/2016)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced ... Food and Drug Administration (FDA) on February 4, 2016, ... on the clinical studies being conducted under the Company,s ... hold impacts part of the clinical work currently being ... clinical trials. --> ...
(Date:2/5/2016)... Feb. 5, 2016  Redwood Scientific Technologies, Inc. announced ... designed to help women balance their hormones. This product ... Jason Cardiff , President and CEO. ... to help the millions of women across the country ... of imbalanced hormones. Our research and development team is ...
Breaking Medicine Technology: